# Jonas Bergh

## List of Publications by Year in descending order



| | | | |
|---|---|---|---|
| 143 papers | 10,788 citations | 71061 41 h-index | 33869 99 g-index |
| 153 all docs | 153 docs citations | 153 times ranked | 16599 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nature Cancer, 2022, 3, 251-261. | 5.7 | 44 |
| 2 | Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. Cancer Research, 2022, 82, GS1-01-GS1-01. | 0.4 | 5 |
| 3 | Risk of heart disease following treatment for breast cancer â€“ results from a population-based cohort study. ELife, 2022, 11, . | 2.8 | 11 |
| 4 | The value of anticancer drugs â€” a regulatory view. Nature Reviews Clinical Oncology, 2022, 19, 207-215. | 12.5 | 14 |
| 5 | Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. Cancers, 2022, 14, 1999. | 1.7 | 5 |
| 6 | Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study. Breast Cancer Research and Treatment, 2022, , 1. | 1.1 | 0 |
| 7 | Impairment of endoxifen formation in tamoxifenâ€treated premenopausal breast cancer patients carrying reducedâ€function CYP2D6 alleles. British Journal of Clinical Pharmacology, 2021, 87, 1243-1252. | 1.1 | 18 |
| 8 | Long-Term Prognostication for 20â€‰114 Women With Small and Node-Negative Breast Cancerâ€, (T1abN0). JNCI Cancer Spectrum, 2021, 5, pkaa084. | 1.4 | 3 |
| 9 | A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Research, 2021, 23, 8. | 2.2 | 15 |
| 10 | Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. Cancers, 2021, 13, 1166. | 1.7 | 31 |
| 11 | CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma. Cancers, 2021, 13, 1175. | 1.7 | 2 |
| 12 | Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. Cardio-Oncology, 2021, 7, 20. | 0.8 | 8 |
| 13 | High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial. Clinical Cancer Research, 2021, 27, 3469-3477. | 3.2 | 8 |
| 14 | A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Research and Treatment, 2021, 189, 15-23. | 1.1 | 6 |
| 15 | Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. Breast Cancer Research and Treatment, 2021, 190, 451-462. | 1.1 | 1 |
| 16 | Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer. Cancers, 2021, 13, 4655. | 1.7 | 6 |
| 17 | Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 99, 102257. | 3.4 | 40 |
| 18 | Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. JAMA Oncology, 2021, 7, 1360. | 3.4 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. Npj Breast Cancer, 2021, 7, 144. | 2.3 | 3 |
| 20 | Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. Acta OncolÃ³gica, 2020, 59, 75-81. | 0.8 | 10 |
| 21 | Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 147-155. | 1.8 | 2 |
| 22 | Efficacy and safety of tailored and doseâ€dense adjuvant chemotherapy and trastuzumab for resected HER2â€positive breast cancer: Results from the phase 3 PANTHER trial. Cancer, 2020, 126, 1175-1182. | 2.0 | 14 |
| 23 | MNK2 governs the macrophage antiinflammatory phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27556-27565. | 3.3 | 24 |
| 24 | European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. ESMO Open, 2020, 5, e000798. | 2.0 | 6 |
| 25 | PD-1 protein and gene expression as prognostic factors in early breast cancer. ESMO Open, 2020, 5, e001032. | 2.0 | 12 |
| 26 | Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. ESMO Open, 2020, 5, e000856. | 2.0 | 1 |
| 27 | Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. Acta OncolÃ³gica, 2020, 59, 1382-1387. | 0.8 | 11 |
| 28 | Chemotherapy use near the end-of-life in patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 181, 645-651. | 1.1 | 10 |
| 29 | A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. Oncogene, 2020, 39, 5430-5440. | 2.6 | 23 |
| 30 | Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. Oncologist, 2020, 25, e709-e715. | 1.9 | 11 |
| 31 | Programmed deathâ€ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21â€gene and 70â€gene signatures in estrogen receptorâ€positive disease. Molecular Oncology, 2020, 14, 951-963. | 2.1 | 18 |
| 32 | Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000â€“1. Acta OncolÃ³gica, 2020, 59, 825-832. | 0.8 | 5 |
| 33 | Long-term (up to 16Âmonths) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. Breast Cancer Research and Treatment, 2020, 181, 87-96. | 1.1 | 6 |
| 34 | Caring for patients with cancer in the COVID-19 era. Nature Medicine, 2020, 26, 665-671. | 15.2 | 269 |
| 35 | Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancerâ€”a prospective nationwide Swedish multicenter study. Human Reproduction, 2020, 35, 929-938. | 0.4 | 58 |
| 36 | CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. Journal of Clinical Investigation, 2020, 130, 1185-1198. | 3.9 | 139 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions â€“ Part II. Stabilization. Seminars in Musculoskeletal Radiology, 2020, 24, 710-725. | 0.4 | 8 |
| 38 | Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions - Part I. Ablation. Seminars in Musculoskeletal Radiology, 2020, 24, 692-709. | 0.4 | 19 |
| 39 | Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. EBioMedicine, 2019, 48, 212-223. | 2.7 | 29 |
| 40 | STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. Cancers, 2019, 11, 1479. | 1.7 | 55 |
| 41 | Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. Clinical Cancer Research, 2019, 25, 5717-5726. | 3.2 | 71 |
| 42 | Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nature Communications, 2019, 10, 2110. | 5.8 | 139 |
| 43 | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. Cancers, 2019, 11, 628. | 1.7 | 51 |
| 44 | The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. Breast Cancer Research, 2019, 21, 34. | 2.2 | 48 |
| 45 | High-intensity exercise during chemotherapy induces beneficial effects 12Âmonths into breast cancer survivorship. Journal of Cancer Survivorship, 2019, 13, 244-256. | 1.5 | 65 |
| 46 | Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Research, 2019, 21, 36. | 2.2 | 36 |
| 47 | An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. Cancer Immunology, Immunotherapy, 2019, 68, 927-936. | 2.0 | 32 |
| 48 | Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€ˆ298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452. | 6.3 | 260 |
| 49 | Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 348-358. | 2.5 | 20 |
| 50 | European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open, 2019, 4, e000570. | 2.0 | 11 |
| 51 | CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. Scientific Reports, 2019, 9, 19384. | 1.6 | 22 |
| 52 | Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. Journal of Clinical Pathology, 2018, 71, 787-794. | 1.0 | 21 |
| 53 | RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 1280-1281. | 3.0 | 1 |
| 54 | Immune gene expression and response to chemotherapy in advanced breast cancer. British Journal of Cancer, 2018, 118, 480-488. | 2.9 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. Breast Cancer Research and Treatment, 2018, 169, 93-103. | 1.1 | 86 |
| 56 | Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). BMC Cancer, 2018, 18, 174. | 1.1 | 22 |
| 57 | Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A populationâ€based cohort study. International Journal of Cancer, 2018, 143, 1093-1104. | 2.3 | 40 |
| 58 | Feasibility of reusing time-matched controls in an overlapping cohort. Statistical Methods in Medical Research, 2018, 27, 1818-1829. | 0.7 | 1 |
| 59 | Assessment of early response biomarkers in relation to longâ€term survival in patients with HER2â€negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. International Journal of Cancer, 2018, 142, 618-628. | 2.3 | 27 |
| 60 | Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Research and Treatment, 2018, 167, 761-769. | 1.1 | 45 |
| 61 | Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. Histopathology, 2018, 72, 974-989. | 1.6 | 70 |
| 62 | Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1818-1831. | 0.5 | 133 |
| 63 | Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nature Communications, 2018, 9, 5150. | 5.8 | 496 |
| 64 | Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. IScience, 2018, 9, 71-83. | 1.9 | 38 |
| 65 | Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34Âyears longitudinal data from the Stockholmâ€“Gotland cancer registry. Breast Cancer Research and Treatment, 2018, 172, 703-712. | 1.1 | 3 |
| 66 | Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients. Pharmacogenomics, 2018, 19, 1259-1268. | 0.6 | 14 |
| 67 | Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene, 2018, 37, 4639-4661. | 2.6 | 219 |
| 68 | Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. OncoImmunology, 2018, 7, e1466017. | 2.1 | 18 |
| 69 | Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. Pharmacogenomics, 2018, 19, 1027-1037. | 0.6 | 10 |
| 70 | Notch signaling promotes a HIF2Î±-driven hypoxic response in multiple tumor cell types. Oncogene, 2018, 37, 6083-6095. | 2.6 | 20 |
| 71 | Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. Breast Cancer Research, 2018, 20, 64. | 2.2 | 40 |
| 72 | Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment, 2018, 168, 349-355. | 1.1 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. Journal of Clinical Investigation, 2018, 128, 1355-1370. | 3.9 | 123 |
| 74 | High expression of stromal PDGFRÎ² is associated with reduced benefit of tamoxifen in breast cancer. Journal of Pathology: Clinical Research, 2017, 3, 38-43. | 1.3 | 29 |
| 75 | Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. Critical Reviews in Oncology/Hematology, 2017, 114, 91-101. | 2.0 | 15 |
| 76 | Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Scientific Reports, 2017, 7, 1089. | 1.6 | 19 |
| 77 | Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. Acta OncolÃ³gica, 2017, 56, 1143-1151. | 0.8 | 8 |
| 78 | RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clinical Breast Cancer, 2017, 17, 585-594.e4. | 1.1 | 39 |
| 79 | A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment. Supportive Care in Cancer, 2017, 25, 1423-1429. | 1.0 | 34 |
| 80 | PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clinical Cancer Research, 2017, 23, 7225-7231. | 3.2 | 17 |
| 81 | Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. Clinical Cancer Research, 2017, 23, 7512-7520. | 3.2 | 43 |
| 82 | Breast cancer in young women and prognosis: How important are proliferation markers?. European Journal of Cancer, 2017, 84, 278-289. | 1.3 | 24 |
| 83 | An HIF-1Î±/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell, 2017, 32, 669-683.e5. | 7.7 | 352 |
| 84 | 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846. | 13.9 | 1,052 |
| 85 | Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology. Journal of Clinical Oncology, 2017, 35, 254-255. | 0.8 | 7 |
| 86 | Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clinical Cancer Research, 2017, 23, 2584-2592. | 3.2 | 15 |
| 87 | Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy. Acta Radiologica, 2017, 58, 394-402. | 0.5 | 25 |
| 88 | Timeâ€dependent risk and predictors of venous thromboembolism in breast cancer patients: A populationâ€based cohort study. Cancer, 2017, 123, 468-475. | 2.0 | 31 |
| 89 | Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. Journal of Clinical Oncology, 2017, 35, 1641-1649. | 0.8 | 555 |
| 90 | Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. BMC Cancer, 2017, 17, 802. | 1.1 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Reply to A.Y. Lin. Journal of Clinical Oncology, 2017, 35, 121-122. | 0.8 | 0 |
| 92 | MICADo â€“ Looking for Mutations in Targeted PacBio Cancer Data: An Alignment-Free Method. Frontiers in Genetics, 2016, 7, 214. | 1.1 | 4 |
| 93 | Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. Scientific Reports, 2016, 6, 38037. | 1.6 | 17 |
| 94 | The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. ESMO Open, 2016, 1, e000004. | 2.0 | 12 |
| 95 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097. | 2.0 | 82 |
| 96 | Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. Cancer Research, 2016, 76, 3166-3178. | 0.4 | 48 |
| 97 | Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. Journal of Infection, 2016, 72, 650-658. | 1.7 | 22 |
| 98 | Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. Molecular Oncology, 2016, 10, 517-525. | 2.1 | 21 |
| 99 | Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. British Journal of Cancer, 2016, 114, 1117-1124. | 2.9 | 57 |
| 100 | Long-term outcome in young women with breast cancer: a population-based study. Breast Cancer Research and Treatment, 2016, 160, 131-143. | 1.1 | 82 |
| 101 | Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. JAMA - Journal of the American Medical Association, 2016, 316, 1888. | 3.8 | 79 |
| 102 | Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 5249-5255. | 3.2 | 12 |
| 103 | The European Cancer Patientâ€™s Bill of Rights, update and implementation 2016. ESMO Open, 2016, 1, e000127. | 2.0 | 36 |
| 104 | An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. Clinical Cancer Research, 2016, 22, 2417-2426. | 3.2 | 8 |
| 105 | Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. Journal of Clinical Oncology, 2016, 34, 895-897. | 0.8 | 0 |
| 106 | Digital image analysis outperforms manual biomarker assessment in breast cancer. Modern Pathology, 2016, 29, 318-329. | 2.9 | 144 |
| 107 | Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. Journal of Clinical Oncology, 2016, 34, 1573-1579. | 0.8 | 15 |
| 108 | Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 386, 433-443. | 6.3 | 444 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment With Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist, 2015, 20, 196-201. | 1.9 | 33 |
| 110 | Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer. Cancer Research, 2015, 75, 2445-2456. | 0.4 | 53 |
| 111 | mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. Cancer Letters, 2015, 367, 76-87. | 3.2 | 45 |
| 112 | Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines â€“ a Swedish survey with central re-assessment. Acta OncolÃ³gica, 2015, 54, 1040-1048. | 0.8 | 27 |
| 113 | Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. Molecular Oncology, 2015, 9, 1384-1391. | 2.1 | 13 |
| 114 | Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. Clinical Proteomics, 2015, 12, 8. | 1.1 | 31 |
| 115 | Tailoring therapiesâ€”improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology, 2015, 26, 1533-1546. | 0.6 | 1,449 |
| 116 | Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells. Journal of the National Cancer Institute, 2015, 107, djv209. | 3.0 | 57 |
| 117 | Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget, 2015, 6, 33306-33318. | 0.8 | 31 |
| 118 | miRâ€206 inhibits cell migration through direct targeting of the actinâ€binding protein Coronin 1C in tripleâ€negative breast cancer. Molecular Oncology, 2014, 8, 1690-1702. | 2.1 | 77 |
| 119 | Superficial scrapings from breast tumors is a source for biobanking and research purposes. Laboratory Investigation, 2014, 94, 796-805. | 1.7 | 10 |
| 120 | The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2â€Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Oncologist, 2014, 19, 766-773. | 1.9 | 20 |
| 121 | First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 921-929. | 0.8 | 244 |
| 122 | FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1919-1925. | 0.8 | 248 |
| 123 | Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. Journal of Clinical Oncology, 2012, 30, 2601-2608. | 0.8 | 411 |
| 124 | Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast, 2012, 21, 507-513. | 0.9 | 36 |
| 125 | Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience.. Journal of Clinical Oncology, 2012, 30, e11510-e11510. | 0.8 | 0 |
| 126 | A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta OncolÃ³gica, 2011, 50, 35-41. | 0.8 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Quo Vadis With Targeted Drugs in the 21st Century?. Journal of Clinical Oncology, 2009, 27, 2-5. | 0.8 | 45 |
| 128 | A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 2009, 15, 68-74. | 15.2 | 566 |
| 129 | Prognostic Significance of Stromal Platelet-Derived Growth Factor Î²-Receptor Expression in Human Breast Cancer. American Journal of Pathology, 2009, 175, 334-341. | 1.9 | 215 |
| 130 | Erratum to â€œHow to treat male breast cancerâ€•[The Breast 16S2 (2007) S147â€“S154]. Breast, 2008, 17, 319 | 0.9 | 2 |
| 131 | Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptorâ€“Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4956-4962. | 0.8 | 52 |
| 132 | Adjuvant chemotherapy for breast cancerâ€”â€œone fits allâ€?. Breast, 2005, 14, 564-569. | 0.9 | 7 |
| 133 | Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?. Lancet, The, 2003, 362, 183-184. | 6.3 | 12 |
| 134 | Chemotherapy of Breast Cancer. American Journal of Cancer, 2002, 1, 165-171. | 0.4 | 0 |
| 135 | Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?. Acta OncolÃ³gica, 2000, 39, 319-326. | 0.8 | 18 |
| 136 | Is There a Role for Intensive Therapy in Breast Cancer?. Acta OncolÃ³gica, 1999, 38, 37-46. | 0.8 | 3 |
| 137 | Suramin in Non-small Cell Lung Cancer and Advanced Breast Cancer: Two Parallel Phase II Studies. Acta OncolÃ³gica, 1997, 36, 171-174. | 0.8 | 28 |
| 138 | Effects of Interferons and Tumour Necrosis Factor-Î± on Human Lung Cancer Cell Lines and the Development of an Interferon-Resistant Lung Cancer Cell Line. Acta OncolÃ³gica, 1996, 35, 473-478. | 0.8 | 5 |
| 139 | Detection of tumor-specific cytotoxic drug activityIN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. International Journal of Cancer, 1994, 56, 715-720. | 2.3 | 71 |
| 140 | Characterization of A U-937 subline which can be induced to differentiate in serum-free medium. International Journal of Cancer, 1992, 50, 153-160. | 2.3 | 13 |
| 141 | Increased Expression of N-myc in Human Small Cell Lung Cancer Biopsies Predicts Lack of Response to Chemotherapy and Poor Prognosis. American Journal of Clinical Pathology, 1987, 88, 216-220. | 0.4 | 91 |
| 142 | Expression of multiple growth factors in a human lung cancer cell line. International Journal of Cancer, 1987, 39, 502-507. | 2.3 | 59 |
| 143 | Amplification of the N-myc oncogene in an adenocarcinoma of the lung. Journal of Cellular Biochemistry, 1986, 31, 297-304. | 1.2 | 20 |